Deformity

OrthoPediatrics Corp. Receives “Breakthrough Device” Designation from FDA for eLLi™ Growing Rod System for Pediatric Patients with Scoliosis

Retrieved on: 
星期四, 五月 2, 2024
EOS, FDA, Public, Safety, Food, De novo, Surgeon, Elective surgery, Pathology, Breakthrough, Spine, Patient, Diagnosis, Deformity, Elli, Scoliosis

eLLi aims to provide a non-invasive means of extending the growing rods that provides increased force, enhanced mechanical reliability, and superior distraction precision, while also addressing safety concerns associated with current technology.

Key Points: 
  • eLLi aims to provide a non-invasive means of extending the growing rods that provides increased force, enhanced mechanical reliability, and superior distraction precision, while also addressing safety concerns associated with current technology.
  • eLLi will allow surgeons a new alternative to address deformity of the growing spine with an advanced technology that will complement our efforts to build a platform of EOS technologies.
  • We are proud to have an expert design team comprised of surgeons who have dedicated their careers to treating these unique patients.
  • David Bailey, OrthoPediatrics’ President & CEO, commented, “Receiving the Breakthrough Device designation from the FDA is a great achievement for our team.

Orphan designation: antisense oligonucleotide targeting exon 73 in the COL7A1 gene Treatment of epidermolysis bullosa, 12/10/2017 Withdrawn

Retrieved on: 
星期四, 四月 18, 2024
Eurostat, Diagnosis, Civil service commission, Gene, Mutation, Epidermolysis bullosa, Skin cancer, Patient, Committee, Knowledge, Regulation, Keratin, EMA, IRIS, Protein, Life expectancy, Deformity, Blister, European, Skin, Collagen, COMP, Infection, Sponsor, European Commission, Safety, Unit, Marketing, COL7A1, Medicine, Pharmaceutical industry

Orphan designation: antisense oligonucleotide targeting exon 73 in the COL7A1 gene Treatment of epidermolysis bullosa, 12/10/2017 Withdrawn

Key Points: 


Orphan designation: antisense oligonucleotide targeting exon 73 in the COL7A1 gene Treatment of epidermolysis bullosa, 12/10/2017 Withdrawn

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Retrieved on: 
星期四, 四月 18, 2024
Eurostat, Diagnosis, Civil service commission, Gene, Anthraquinones, Skin cancer, Epidermolysis bullosa, Disease, Inflammation, Patient, Committee, Knowledge, Regulation, Keratin, EMA, IRIS, Joint, Protein, Life expectancy, Deformity, Blister, Interleukin-1 family, Mouth, European, Skin, Collagen, COMP, Infection, Safety, European Commission, Pain, Osteoarthritis, Marketing, Swelling, FGK, Medicine, Pharmaceutical industry

Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Key Points: 


Orphan designation: Diacerein Treatment of epidermolysis bullosa, 20/02/2014 Positive

Protein ice cream company wins 2024 Rice Business Plan Competition

Retrieved on: 
星期一, 四月 8, 2024
Friends, Ulcer, University, Obstructive sleep apnea, Rice University, Entrepreneurship, Bacteria, Deformity, Love, Harvard University, Chevron Corporation, RWTH Aachen University, Chemical engineering, Reiss, Podiatry, University of Houston, Greater Houston, Foot, TiE, Mentorship, Northwestern University, Rice, University of California, Berkeley, WRX, Carnegie Mellon University, Yale University, University of Kansas, EY, Tulane University, Ice cream, Michigan State University, Johns Hopkins University, Heart, Intuitive Machines

HOUSTON, April 8, 2024 /PRNewswire/ -- Ice cream company Protein Pints took home the grand prize at the 2024 Rice Business Plan Competition (RBPC) April 6 as the best student ventures from top universities across the world competed for prizes in front of nearly 350 angel, venture capital and corporate investors and members of the business community.

Key Points: 
  • HOUSTON, April 8, 2024 /PRNewswire/ -- Ice cream company Protein Pints took home the grand prize at the 2024 Rice Business Plan Competition (RBPC) April 6 as the best student ventures from top universities across the world competed for prizes in front of nearly 350 angel, venture capital and corporate investors and members of the business community.
  • The best student ventures from top universities across the world competed in the 2024 Rice Business Plan Competition.
  • Hosted annually by the Rice Alliance for Technology and Entrepreneurship and Rice University's Jones Graduate School of Business , the RBPC is the world's largest and richest student startup competition.
  • Protein Pints is a high-protein, low-sugar, ice cream product designed for people who would benefit from having access to a functional ice cream and/or better tasting and more enjoyable protein options.

Dr. Mark Viktor Silver – Maintains Unique Double Board Certification

Retrieved on: 
星期一, 三月 11, 2024
Health, Surgery, Neurology, Practice Management, Physical Therapy, General Health, University, Certification, McGill University, ABNS, Arm, Specialization, Surgeon, Column (periodical), Medical college, Patient, Neurosurgery, Human, General surgery, Neck, Deformity, Scoliosis, Spine, Physician, Royal college, School

Dr. Mark Viktor Silver , founder of the Silver Spine and Neurological Center , has maintained the unique distinction of being board-certified in neurosurgery by both the American Board of Neurological Surgery (ABNS) and the Royal College of Physicians and Surgeons of Canada.

Key Points: 
  • Dr. Mark Viktor Silver , founder of the Silver Spine and Neurological Center , has maintained the unique distinction of being board-certified in neurosurgery by both the American Board of Neurological Surgery (ABNS) and the Royal College of Physicians and Surgeons of Canada.
  • With more than 20 years of practice, Dr. Silver specializes in minimally invasive and complex neurosurgical procedures aimed at alleviating neck, back, arm, and leg pain.
  • “While not required for a medical license, the rigorous board certification process shows a physician’s commitment to his patients and profession,” said Dr. Silver.
  • With 21 years of professional practice, Dr Silver has worked in large academic and private institutions and has served as Chief of Neurosurgery at various prestigious hospitals.

Steps2Walk Announces the Impact of Q1 Surgical Mission and Orthopedic Training Programs

Retrieved on: 
星期四, 四月 4, 2024
Walking, Partnership, Education, Patient, Foot, Child, Cadaver, Telehealth, Surgeon, Deformity, DRS, Nursing

DENVER, April 4, 2024 /PRNewswire-PRWeb/ -- Steps2Walk, a global humanitarian nonprofit organization providing surgical missions and surgeon training in under-served regions around the world, today announced the patient and educational impact of its first round of programs for 2024. In February and March, the organization conducted programs in Sri Lanka, Pakistan, and for the first time, Tanzania, treating 50 patients and providing surgical training and education to 120 local surgeons.

Key Points: 
  • Founded in 2000 by world-renowned orthopedic surgeon Dr. Mark Myerson , the organization addresses the surgical needs of those with severe foot and ankle deformities in regions where there is limited orthopedic care.
  • Each mission is organized in partnership with the Steps2Walk team, their international network of volunteer surgeons and the hosting medical institutions.
  • Steps2Walk has four upcoming programs scheduled for Q2:
    For more information on how to become a volunteer faculty member or trainee participant in one of the Steps2Walk Programs, visit https://steps2walk.org/faculty/ .
  • Steps2Walk also accepts donations , which can give the gift of walking to those most in need and help fund critical training and education for regional orthopedic surgeons.

OFFICIAL LAUNCH OF THE NATIONAL UNIVERSITY SPINE INSTITUTE (NUSI): LEADING SPINE CARE INTO THE FUTURE

Retrieved on: 
星期六, 三月 30, 2024
NUH, Research, Spinal stenosis, Conference, Health, MRI, National University Health System, Column (periodical), Radiology, Associate, Magnetic resonance imaging, Consultant, Education, Orthopedic surgery, Patient, Ageing, Degenerative disc disease, Knowledge, Artificial intelligence, Human, Deep learning, Deformity, National University Hospital, Scoliosis, Osteoporosis, Spine, Pain management, NUHS, Rehabilitation, Person, Nursing

SINGAPORE, March 30, 2024 /PRNewswire/ -- The National University Spine Institute (NUSI) is a new dedicated specialist spine institute under the National University Health System (NUHS) that provides multidisciplinary care for patients with spinal diseases and deformities.

Key Points: 
  • SINGAPORE, March 30, 2024 /PRNewswire/ -- The National University Spine Institute (NUSI) is a new dedicated specialist spine institute under the National University Health System (NUHS) that provides multidisciplinary care for patients with spinal diseases and deformities.
  • Under the leadership of Associate Professor Gabriel Liu, NUSI aims to set new standards in spine care through a patient-centric approach.
  • A/Prof Liu said: "NUSI differentiates itself by providing dedicated sub-specialties within the spine practice, standardising work processes and providing value-driven patient care across the cluster to address spinal problems.
  • NUSI is dedicated to developing community care programmes for patients, with cases expected to rise in the coming years partly due to an ageing population."

PathKeeper Surgical enters into know-how agreement with Mayo Clinic for low-radiation pediatric spine surgery

Retrieved on: 
星期一, 三月 25, 2024
MD, Radiation, Deformity, Machine learning, Mayo Clinic, KFAR, Research, Patient, Surgeon, Standard of care, Scoliosis, Safety, Dentistry

KFAR SABA, Israel, March 25, 2024 /PRNewswire/ -- PathKeeper Surgical, an Israeli medical technology company committed to advancing surgical solutions through innovative camera and machine learning technologies, announced it has entered into a know-how agreement with Mayo Clinic to research radiation levels in pediatric spine surgeries. The research will focus on reducing patient radiation exposure using minimally invasive optical navigation and utilizing intraoperative measurement tools for scoliosis correction, including vertebral body tethering.

Key Points: 
  • PathKeeper Surgical enters a know-how agreement with Mayo Clinic in Rochester, MN.
  • To address the unique challenges of pediatric patients undergoing spine surgery for scoliosis, Mayo Clinic pediatric spine surgeons Noelle Larson, MD, and Todd Milbrandt, MD, are collaborating with PathKeeper Surgical, a company widely known for its cutting-edge optical navigation that prioritize precision, safety, and minimization of radiation exposure.
  • "We are proud to collaborate with Mayo Clinic," said Erez Lampert, founder and Chief Executive Officer at PathKeeper Surgical.
  • The research and development efforts will include refining and expanding the application of PathKeeper's technology to tackle the unique challenges posed by pediatric spine surgery.

OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
星期三, 三月 6, 2024
Acquisition, Deformity, International, Total, Infection, Investment, Marketing, Growth, Fixation (psychology), Response, Elective surgery, Orthopediatrics, Event, OPSB, Scoliosis, Webcast, Sport, Depreciation, Video game

Total revenue for the fourth quarter of 2023 was $37.6 million, a 21% increase compared to $31.0 million for the same period last year.

Key Points: 
  • Total revenue for the fourth quarter of 2023 was $37.6 million, a 21% increase compared to $31.0 million for the same period last year.
  • The increase in revenue in the fourth quarter of 2023 was driven primarily by growth across Trauma and Deformity, Scoliosis, and OPSB.
  • In the fourth quarter of 2023, we realized an immaterial fair value adjustment benefit compared to a $0.5 million benefit for the fourth quarter of 2022.
  • Adjusted EBITDA for the fourth quarter of 2023 was $1.3 million as compared to a loss of $2.2 million for the fourth quarter of 2022.

SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance

Retrieved on: 
星期一, 二月 26, 2024
International, Investment, Physician, Record, Worldwide, CPT, Deformity, DSM-IV codes, Webcast, Patient, Anatomy, Research, Travel, Depreciation, Pharmaceutical industry

Gross margin was ~74% for the fourth quarter 2023, compared to ~84% in the corresponding period in 2022.

Key Points: 
  • Gross margin was ~74% for the fourth quarter 2023, compared to ~84% in the corresponding period in 2022.
  • The fourth quarter 2023 gross margin also reflects a ~4 percentage point reduction from a $1.7 million excess inventory reserve.
  • Operating expenses increased ~8% to $41.2 million in the fourth quarter 2023, compared to $38.2 million in the corresponding period in 2022.
  • SI-BONE will host a conference call to discuss the fourth quarter 2023 financial results after market close on Monday, February 26, 2024 at 4:30 P.M. Eastern Time.